Cargando…

Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery

Supra‐maximum surgical tumor resection without neurological damage is highly valuable for treatment and prognosis of patients with glioblastoma multiforme (GBM). We developed a GBM‐specific fluorescence probe using IRDye800CW (peak absorption/emission, 778/795 nm) and bombesin (BBN), which (IRDye800...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Kunshan, Chi, Chongwei, Li, Deling, Zhang, Jingjing, Niu, Gang, Lv, Fangqiao, Wang, Junmei, Che, Wenqiang, Zhang, Liwei, Ji, Nan, Zhu, Zhaohui, Tian, Jie, Chen, Xiaoyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823121/
https://www.ncbi.nlm.nih.gov/pubmed/33532584
http://dx.doi.org/10.1002/btm2.10182
_version_ 1783639767498358784
author He, Kunshan
Chi, Chongwei
Li, Deling
Zhang, Jingjing
Niu, Gang
Lv, Fangqiao
Wang, Junmei
Che, Wenqiang
Zhang, Liwei
Ji, Nan
Zhu, Zhaohui
Tian, Jie
Chen, Xiaoyuan
author_facet He, Kunshan
Chi, Chongwei
Li, Deling
Zhang, Jingjing
Niu, Gang
Lv, Fangqiao
Wang, Junmei
Che, Wenqiang
Zhang, Liwei
Ji, Nan
Zhu, Zhaohui
Tian, Jie
Chen, Xiaoyuan
author_sort He, Kunshan
collection PubMed
description Supra‐maximum surgical tumor resection without neurological damage is highly valuable for treatment and prognosis of patients with glioblastoma multiforme (GBM). We developed a GBM‐specific fluorescence probe using IRDye800CW (peak absorption/emission, 778/795 nm) and bombesin (BBN), which (IRDye800‐BBN) targets the gastrin‐releasing peptide receptor, and evaluated the image‐guided resection efficiency, sensitivity, specificity, and survivability. Twenty‐nine patients with newly diagnosed GBM were enrolled. Sixteen hours preoperatively, IRDye800‐BBN (1 mg in 20 ml sterile water) was intravenously administered. A customized fluorescence surgical navigation system was used intraoperatively. Postoperatively, enhanced magnetic resonance images were used to assess the residual tumor volume, calculate the resection extent, and confirm whether complete resection was achieved. Tumor tissues and nonfluorescent brain tissue in adjacent noneloquent boundary areas were harvested and assessed for diagnostic accuracy. Complete resection was achieved in 82.76% of patients. The median extent of resection was 100% (range, 90.6–100%). Eighty‐nine samples were harvested, including 70 fluorescence‐positive and 19 fluorescence‐negative samples. The sensitivity and specificity of IRDye800‐BBN were 94.44% (95% CI, 85.65–98.21%) and 88.24% (95% CI, 62.25–97.94%), respectively. Twenty‐five patients were followed up (median, 13.5 [3.1–36.0] months), and 14 had died. The mean preoperative and immediate and 6‐month postoperative Karnofsky performance scores were 77.9 ± 11.8, 71.3 ± 19.2, and 82.6 ± 14.7, respectively. The median overall and progression‐free survival were 23.1 and 14.1 months, respectively. In conclusion, GBM‐specific fluorescent IRDye800‐BBN can help neurosurgeons identify the tumor boundary with sensitivity and specificity, and may improve survival outcomes.
format Online
Article
Text
id pubmed-7823121
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-78231212021-02-01 Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery He, Kunshan Chi, Chongwei Li, Deling Zhang, Jingjing Niu, Gang Lv, Fangqiao Wang, Junmei Che, Wenqiang Zhang, Liwei Ji, Nan Zhu, Zhaohui Tian, Jie Chen, Xiaoyuan Bioeng Transl Med Research Reports Supra‐maximum surgical tumor resection without neurological damage is highly valuable for treatment and prognosis of patients with glioblastoma multiforme (GBM). We developed a GBM‐specific fluorescence probe using IRDye800CW (peak absorption/emission, 778/795 nm) and bombesin (BBN), which (IRDye800‐BBN) targets the gastrin‐releasing peptide receptor, and evaluated the image‐guided resection efficiency, sensitivity, specificity, and survivability. Twenty‐nine patients with newly diagnosed GBM were enrolled. Sixteen hours preoperatively, IRDye800‐BBN (1 mg in 20 ml sterile water) was intravenously administered. A customized fluorescence surgical navigation system was used intraoperatively. Postoperatively, enhanced magnetic resonance images were used to assess the residual tumor volume, calculate the resection extent, and confirm whether complete resection was achieved. Tumor tissues and nonfluorescent brain tissue in adjacent noneloquent boundary areas were harvested and assessed for diagnostic accuracy. Complete resection was achieved in 82.76% of patients. The median extent of resection was 100% (range, 90.6–100%). Eighty‐nine samples were harvested, including 70 fluorescence‐positive and 19 fluorescence‐negative samples. The sensitivity and specificity of IRDye800‐BBN were 94.44% (95% CI, 85.65–98.21%) and 88.24% (95% CI, 62.25–97.94%), respectively. Twenty‐five patients were followed up (median, 13.5 [3.1–36.0] months), and 14 had died. The mean preoperative and immediate and 6‐month postoperative Karnofsky performance scores were 77.9 ± 11.8, 71.3 ± 19.2, and 82.6 ± 14.7, respectively. The median overall and progression‐free survival were 23.1 and 14.1 months, respectively. In conclusion, GBM‐specific fluorescent IRDye800‐BBN can help neurosurgeons identify the tumor boundary with sensitivity and specificity, and may improve survival outcomes. John Wiley & Sons, Inc. 2020-08-31 /pmc/articles/PMC7823121/ /pubmed/33532584 http://dx.doi.org/10.1002/btm2.10182 Text en © 2020 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of The American Institute of Chemical Engineers. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Reports
He, Kunshan
Chi, Chongwei
Li, Deling
Zhang, Jingjing
Niu, Gang
Lv, Fangqiao
Wang, Junmei
Che, Wenqiang
Zhang, Liwei
Ji, Nan
Zhu, Zhaohui
Tian, Jie
Chen, Xiaoyuan
Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery
title Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery
title_full Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery
title_fullStr Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery
title_full_unstemmed Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery
title_short Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery
title_sort resection and survival data from a clinical trial of glioblastoma multiforme‐specific irdye800‐bbn fluorescence‐guided surgery
topic Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823121/
https://www.ncbi.nlm.nih.gov/pubmed/33532584
http://dx.doi.org/10.1002/btm2.10182
work_keys_str_mv AT hekunshan resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT chichongwei resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT lideling resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT zhangjingjing resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT niugang resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT lvfangqiao resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT wangjunmei resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT chewenqiang resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT zhangliwei resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT jinan resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT zhuzhaohui resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT tianjie resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT chenxiaoyuan resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery